Cancer immunotherapy has been extremely successful in curing patients over the last decade. Immune checkpoint blockades (ICBs) that unleash the brakes in T-cells to promote cytotoxicity against cancer cells are the most successful forms of cancer immunotherapy, yet therapeutic efficacy needs to be improved as only a fraction of patients responds. Dendritic cells (DCs) are immune cells that prime immune responses by collecting information in tumour tissues, and carrying that information to T-cells, thus delivering proper information to DCs is essential. Biomaterial-based approaches can be powerful tools for this purpose, as biomaterials allow us to deliver a variety of immunotherapeutic agents at the right time and place. Herein, we review the key concepts of cancer immunotherapy; discuss the principles for designing biomaterials to deliver immunomodulatory molecules; and outline biomaterial-based strategies to prime anti-cancer immune responses. Specifically, we focus on two widely used forms of biomaterials, multifunctional nanoparticles and biocompatible scaffolds.
Get full access to this article
View all access options for this article.
References
1.
HanahanDWeinbergRA.The hallmarks of cancer. Cell. 2000;100(1):57–70.
2.
ChabnerBARobertsTG.Chemotherapy and the war on cancer. Nat Rev Cancer. 2005;5:65–72.
3.
MellmanICoukosGDranoffG.Cancer immunotherapy comes of age. Nature. 2011;480:480.
4.
SchreiberRDOldLJSmythMJ.Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570.
5.
SharmaPAllisonJP.Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–214.
6.
RibasAWolchokJD.Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355.
7.
PostowMASidlowRHellmannMD.Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168.
8.
SteinmanRMBanchereauJ.Taking dendritic cells into medicine. Nature. 2007;499:419–426.
9.
WculekSKCuetoFJMujalAMDendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7–24.
10.
JuneCHO’ConnorRSKawalekarOUCAR t cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.
11.
PatelSAMinnAJ.Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48(3):417–433.
12.
VonderheideRH.The immune revolution: a case for priming, not checkpoint. Cancer Cell. 2018;33(4):563–569.
13.
PeerDKarpJMHongSNanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751.
14.
ShiJKantoffPWWoosterRCancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20.
15.
FanWYungBHuangPNanotechnology for multimodal synergistic cancer therapy. Chem Rev. 2017;117(22):13566–13638.
16.
DruryJLMooneyDJ.Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials. 2003;24(24):4337–4351.
17.
O’brienFJ.Biomaterials & scaffolds for tissue engineering. Mater Today. 2011;14(3):88–95.
18.
ChenDSMellmanI.Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
19.
TakeuchiOAkiraS.Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–820.
GubinMMArtyomovMNMardisERTumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413–3421.
23.
YarchoanMJohnsonBAIIILutzERTargeting neoantigens to augment antitumor immunity. Nat Rev Cancer. 2017;17:209.
24.
AmmiRDe WaeleJWillemenYPoly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther. 2015;146:120–131.
25.
Mata-HaroVCekicCMartinMThe vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316(5831):1628–1632.
26.
WeeratnaRDMakinenSRMcCluskieMJTLR agonists as vaccine adjuvants: comparison of CpG ODN and resiquimod (R-848). Vaccine. 2005;23(45):5263–5270.
27.
VonderheideRHGlennieMJ.Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19(5):1035–1043.
28.
DranoffG.GM-CSF-based cancer vaccines. Immunol Rev. 2002;188(1):147–154.
29.
DubenskyTWKanneDBLeongML.Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Ther Adv Vaccines. 2013;1(4):131–143.
30.
GalluzziLBuquéAKeppOImmunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111.
31.
KlugFPrakashHHuberPELow-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589–602.
32.
TsaiCSChenFHWangCCMacrophages from irradiated tumors express higher levels of iNOS, Arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys. 2007;68(2):499–507.
33.
ZhongYMengFDengCLigand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules. 2014;15(6):1955–1969.
34.
KarlssonJVaughanHJGreenJJ.Biodegradable polymeric nanoparticles for therapeutic cancer treatments. Annu Rev Chem Biomol Eng. 2018;9(1):105–127.
35.
KamalyNYameenBWuJDegradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602–2663.
36.
Iturrioz-RodríguezNCorrea-DuarteMAFanarragaML.Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles. Int J Nanomedicine. 2019;14:3389.
37.
MichaudMMartinsISukkurwalaAQAutophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334(6062):1573–1577.
38.
ObeidMPanaretakisTJozaNCalreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;14:1848–1850.
39.
ApetohLGhiringhelliFTesniereAThe interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220(1):47–59.
40.
MinYRocheKCTianSAntigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol. 2017;12:877.
41.
WangMSongJZhouFNIR-triggered Phototherapy and immunotherapy via an antigen-capturing Nanoplatform for metastatic cancer treatment. Adv Sci. 2019;6(10):1802157.
42.
WangRHeZCaiPSurface-Functionalized modified copper sulfide nanoparticles enhance checkpoint blockade tumor immunotherapy by photothermal therapy and antigen Capturing. ACS Appl Mater Interfaces. 2019;11(15):13964–13972.
43.
FanYKuaiRXuYImmunogenic cell death amplified by co-localized adjuvant delivery for cancer immunotherapy. Nano Lett. 2017;17(12):7387–7393.
44.
WilsonJTKellerSManganielloMJpH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano. 2013;7(5):3912–3925.
45.
XuZWangYZhangLNanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano. 2014;8(4):3636–3645.
46.
XuZRamishettiSTsengY-CMultifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release. 2013;172(1):259–265.
47.
LiuS-YWeiWYueHNanoparticles-based multi-adjuvant whole cell tumor vaccine for cancer immunotherapy. Biomaterials. 2013;34(33):8291–8300.
48.
LuoMWangHWangZA STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2017;12:648.
49.
GalluzziLBuqueAKeppOImmunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714.
50.
AuKMBalhornRBalhornMCHigh-performance concurrent chemo-immuno-radiotherapy for the treatment of hematologic cancer through selective high-affinity ligand antibody mimic-functionalized doxorubicin-encapsulated nanoparticles. ACS Cent Sci. 2019;5(1):122–144.
51.
KuaiRYuanWSonSElimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci Adv. 2018;4(4):eaao1736.
52.
WeiJLongYGuoRMultifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer. Acta Pharm Sin B. 2019;9(4):819–831.
53.
LiuYQiaoLZhangSDual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Acta Biomater. 2018;66(15):310–324.
54.
ChenQLiuLLuYTumor microenvironment-triggered aggregated magnetic nanoparticles for reinforced image-guided immunogenic chemotherapy. Adv Sci. 2019;6(6):1802134.
55.
BeggACStewartFAVensC.Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11:239–253.
NgwaWIraborOCSchoenfeldJDUsing immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18:313.
58.
HainfeldJFDilmanianFASlatkinDNRadiotherapy enhancement with gold nanoparticles. J Pharm Pharmacol. 2008;60(8):977–985.
59.
SarriaGRFrancésMÁBGalianaIL.Enhancing radiotherapy effect in breast cancer with nanoparticles: a review. Reports Pract Oncol Radiother. 2019;24(1):65–67.
60.
WangCLiXWangYEnhancement of radiation effect and increase of apoptosis in lung cancer cells by thio-glucose-bound gold nanoparticles at megavoltage radiation energies. J Nanoparticle Res. 2013;15:1642.
61.
RimaWSanceyLAloyMTInternalization pathways into cancer cells of gadolinium-based radiosensitizing nanoparticles. Biomaterials. 2013;34(1):181–195.
62.
MaggiorellaLBarouchGDevauxCNanoscale radiotherapy with hafnium oxide nanoparticles. Futur Oncol. 2012;8(9):1167–1181.
TownleyHEKimJDobsonPJ.In vivo demonstration of enhanced radiotherapy using rare earth doped titania nanoparticles. Nanoscale. 2012;4:5043–5050.
65.
MirjoletCPapaALCréhangeGThe radiosensitization effect of titanate nanotubes as a new tool in radiation therapy for glioblastoma: a proof-of-concept. Radiother Oncol. 2013;108(1):136–142.
66.
SongGChengLChaoYEmerging nanotechnology and advanced materials for cancer radiation therapy. Adv Mater. 2017;29(32):1700996.
67.
XieJGongLZhuSEmerging strategies of nanomaterial-mediated tumor radiosensitization. Adv Mater. 2019;31(3):1802244.
68.
KimMSLeeEJKimJWGold nanoparticles enhance anti-tumor effect of radiotherapy to hypoxic tumor. Radiat Oncol J. 2016;34(3):230–238.
69.
ChenQChenJYangZNanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv Mater. 2019;31(10):1802228.
70.
ShibuESHamadaMMuraseNNanomaterials formulations for photothermal and photodynamic therapy of cancer. J Photochem Photobiol C Photochem Rev. 2013;15:53–72.
71.
KimHSLeeDY.Near-infrared-responsive cancer photothermal and photodynamic therapy using gold nanoparticles. Polymers (Basel). 2018;10(9):961.
72.
RajkumarSPrabaharanM.Theranostics based on iron oxide and gold nanoparticles for imaging-guided photothermal and photodynamic therapy of cancer. Curr Top Med Chem. 2017;17:1858–1871.
73.
HouXTaoYPangYNanoparticle-based photothermal and photodynamic immunotherapy for tumor treatment. Int J Cancer. 2018;143(12):3050–3060.
74.
NgCWLiJPuK.Recent progresses in phototherapy-synergized cancer immunotherapy. Adv Funct Mater. 2018;28(46):1804688.
75.
HildebrandtBWustPAhlersOThe cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33–56.
76.
EvansSSRepaskyEAFisherDT.Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015;15:335–349.
77.
ZhouFNordquistREChenWR.Photonics immunotherapy – a novel strategy for cancer treatment. J Innov Opt Health Sci. 2016;9:1630001.
78.
QinZWangYRandrianalisoaJQuantitative comparison of photothermal heat generation between gold nanospheres and nanorods. Sci Rep. 2016;6:29836.
79.
TaoYJuERenJImmunostimulatory oligonucleotides-loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy. Biomaterials. 2014;35(37):9963–9971.
80.
LimJHKimDEKimEJFunctional graphene oxide-based nanosheets for photothermal therapy. Macromol Res. 2018;26:557–565.
81.
LiNSunQYuZNuclear-targeted photothermal therapy prevents cancer recurrence with near-infrared triggered copper sulfide nanoparticles. ACS Nano. 2018;12(6):5197–5206.
82.
LiYLuWHuangQCopper sulfide nanoparticles for photothermal ablation of tumor cells. Nanomedicine. 2010;5:1161–1171.
CheongW-FPrahlSAWelchAJ.A review of the optical properties of biological tissues. IEEE J Quantum Electron. 1990;26(12):2166–2185.
85.
RweiAYWangWKohaneDS.Photoresponsive nanoparticles for drug delivery. Nano Today. 2015;10(4):451–467.
86.
GuoLYanDDYangDCombinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles. ACS Nano. 2014;8(6):5670–5681.
87.
WangCXuLLiangCImmunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv Mater. 2014;26(48):8154–8162.
88.
DuanXChanCLinW.Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chemie – Int Ed. 2019;58(3):670–680.
89.
ChatterjeeDKFongLSZhangY.Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008;60(15):1627–1637.
90.
YuXGaoDGaoLInhibiting metastasis and preventing tumor relapse by triggering host immunity with tumor-targeted photodynamic therapy using photosensitizer-loaded functional nanographenes. ACS Nano. 2017;11(10):10147–10158.
91.
DuanXChanCGuoNPhotodynamic therapy mediated by nontoxic core-shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and antimetastatic effect on breast cancer. J Am Chem Soc. 2016;138(51):16686–16695.
92.
WilhelmSTavaresAJDaiQAnalysis of nanoparticle delivery to tumors. Nat Rev Mater. 2016;1:16014.
93.
MehlenPPuisieuxA.Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449.
94.
ParkCGHartlCASchmidDExtended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci Transl Med. 2018;10(433):eaar1916.
95.
PhuengkhamHSongCUmSHImplantable synthetic immune niche for spatiotemporal modulation of tumor-derived immunosuppression and systemic antitumor immunity: postoperative immunotherapy. Adv Mater. 2018;30(18):1706719.
96.
PhuengkhamHSongCLimYT.A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy. Adv Mater. 2019;31(42):1903242.
97.
WangCWangJZhangXIn situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci Transl Med. 2018;10(429):eaan3682.
98.
SongCPhuengkhamHKimYSSyringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence. Nat Commun. 2019;10:1–15.
99.
ChenQWangCZhangXIn situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2019;14:89–97.
100.
MatlungHLSzilagyiKBarclayNAThe CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276(1):145–164.
101.
ReddySTSwartzMAHubbellJA.Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006;27(12):573–579.
102.
JoshiMDUngerWJStormGTargeting tumor antigens to dendritic cells using particulate carriers. J Control Release. 2012;161(1):25–37.
103.
TrevaskisNLKaminskasLMPorterCJH.From sewer to saviour – targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. 2015;14:781.
104.
SetyawatiMITayCYBayBHGold nanoparticles induced endothelial leakiness depends on particle size and endothelial cell origin. ACS Nano. 2017;11(5):5020–5030.
105.
SchudelAFrancisDMThomasSN.Material design for lymph node drug delivery. Nat Rev Mater. 2019;4:415–428.
CuiZHanS-JHuangL.Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm Res. 2004;21:1018–1025.
108.
KimTHJinHKimHWMannosylated chitosan nanoparticle–based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol Cancer Ther. 2006;5(7):1723–1732.
109.
KwonYJJamesEShastriNIn vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles. Proc Natl Acad Sci. 2005;102:18264–18268.
110.
SteadSOMcInnesSJPKiretaSManipulating human dendritic cell phenotype and function with targeted porous silicon nanoparticles. Biomaterials. 2018;155:92–102.
111.
SteadSOKiretaSMcInnesSJPMurine and non-human primate dendritic cell targeting nanoparticles for in vivo generation of regulatory T-cells. ACS Nano. 2018;12(7):6637–6647.
112.
SehgalKRaghebRFahmyTMNanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15–dependent DC crosstalk. J Immunol. 2014;193(5):2297–2305.
113.
XiangSDScholzenAMinigoGPathogen recognition and development of particulate vaccines: does size matter?Methods. 2006;40(1):1–9.
114.
JoshiVBGearySMSalemAK.Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2013;15:85–94.
115.
FytianosKRodriguez-LorenzoLCliftMJDUptake efficiency of surface modified gold nanoparticles does not correlate with functional changes and cytokine secretion in human dendritic cells in vitro. Nanomedicine Nanotechnology, Biol Med. 2015;11(3):633–644.
116.
MoyanoDFGoldsmithMSolfiellDJNanoparticle hydrophobicity dictates immune response. J Am Chem Soc. 2012;134(9):3965–3967.
117.
SeongS-YMatzingerP.Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4:469.
118.
ShimaFAkagiTUtoTManipulating the antigen-specific immune response by the hydrophobicity of amphiphilic poly (γ-glutamic acid) nanoparticles. Biomaterials. 2013;34(37):9709–9716.
119.
NiikuraKMatsunagaTSuzukiTGold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS Nano. 2013;7(5):3926–3938.
120.
De KokerSCuiJVanparijsNEngineering polymer hydrogel nanoparticles for lymph Node-targeted delivery. Angew Chemie Int Ed. 2016;55(4):1334–1339.
121.
KaminskasLMPorterCJH.Targeting the lymphatics using dendritic polymers (dendrimers). Adv Drug Deliv Rev. 2011;63(10-11):890–900.
122.
ZengQLiHJiangHTailoring polymeric hybrid micelles with lymph node targeting ability to improve the potency of cancer vaccines. Biomaterials. 2017;122:105–113.
123.
LiuHMoynihanKDZhengYStructure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507:519.
124.
KoshySTMooneyDJ.Biomaterials for enhancing anti-cancer immunity. Curr Opin Biotechnol. 2016;40:1–8.
125.
AliOAHuebschNCaoLInfection-mimicking materials to program dendritic cells in situ. Nat Mater. 2009;8:151.
126.
AliOATayaliaPShvartsmanDInflammatory cytokines presented from polymer matrices differentially generate and activate DCs in situ. Adv Funct Mater. 2013;23(36):4621–4628.
127.
KimJLiWAChoiYInjectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol. 2015;33:64.
128.
LiZBarnesJCBosoyAMesoporous silica nanoparticles in biomedical applications. Chem Soc Rev. 2012;41:2590–2605.
129.
WangYZhaoQHanNMesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomed Nanotechnol Biol Med. 2015;11(2):313–327.
130.
NguyenTLChoiYKimJ.Mesoporous silica as a versatile platform for cancer immunotherapy. Adv Mater. 2019;31(34):1803953.
131.
LiAWSobralMCBadrinathSA facile approach to enhance antigen response for personalized cancer vaccination. Nat Mater. 2018;17:528.
132.
BencherifSASandsRWAliOAInjectable cryogel-based whole-cell cancer vaccines. Nat Commun. 2015;6:7556.
133.
Bauleth-RamosTShihTShahbaziMAcetalated dextran nanoparticles loaded into an injectable alginate cryogel for combined chemotherapy and cancer vaccination. Adv Funct Mater. 2019;29(35):1903686.
134.
ShihTBlacklowSOLiAWInjectable, tough alginate cryogels as cancer vaccines. Adv Healthc Mater. 2018;7(10):1701469.
135.
ChenDSMellmanI.Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–330.
136.
SahinUTüreciÖ. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355–1360.
137.
SchumacherTNScheperWKvistborgP.Cancer neoantigens. Annu Rev Immunol. 2019;37:173–200.
138.
AliOADohertyEMooneyDJRelationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines. Biomatter. 2011;1(1):66–75.
139.
JoSDNamGHKwakGHarnessing designed nanoparticles: Current strategies and future perspectives in cancer immunotherapy. Nano Today. 2017;17:23–37.
